Novavax in selloff after RFK Jr.’s comments on COVID vaccine

Seeking Alpha News (Thu, 10-Apr 10:28 AM)

  • Novavax (NASDAQ:NVAX) shares sold off on Thursday after Health Secretary Robert F. Kennedy Jr. cast doubts about the efficacy of the company's COVID shot amid a delay for its full approval.
  • Early this month, The Wall Street Journal reported that after the resignation of its chief vaccine regulator, Dr. Peter Marks, the FDA has missed a key deadline to grant full approval for NVAX’s shot, currently allowed under the emergency use authorization.
  • During an interview with Dr. Jon Lapook of CBS News, RFK Jr. attributed the delay to the vaccine’s single antigen composition, which he said has never worked against respiratory diseases.
  • “We’re looking at that vaccine, and it is a single-antigen vaccine. And, for respiratory illnesses, the single antigen vaccines have never worked,” RFK Jr. said, adding that “we are actually shifting our priorities to multiple-antigen vaccines. And NIH is already working on a number of those.”